Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Orthofix Medical (OFIX) EBITDA (2016 - 2025)

Orthofix Medical (OFIX) has disclosed EBITDA for 16 consecutive years, with -$73.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 64.41% year-over-year to -$73.1 million, compared with a TTM value of -$87.3 million through Dec 2025, up 54.64%, and an annual FY2025 reading of -$87.3 million, up 32.35% over the prior year.
  • EBITDA was -$73.1 million for Q4 2025 at Orthofix Medical, down from -$23.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $221.3 million in Q4 2023 and bottomed at -$205.3 million in Q4 2024.
  • Average EBITDA over 5 years is -$3.1 million, with a median of -$2.5 million recorded in 2021.
  • The sharpest move saw EBITDA skyrocketed 737.62% in 2021, then crashed 951.15% in 2023.
  • Year by year, EBITDA stood at $61.3 million in 2021, then fell by 8.55% to $56.0 million in 2022, then surged by 294.96% to $221.3 million in 2023, then plummeted by 192.8% to -$205.3 million in 2024, then surged by 64.41% to -$73.1 million in 2025.
  • Business Quant data shows EBITDA for OFIX at -$73.1 million in Q4 2025, -$23.1 million in Q3 2025, and -$10.6 million in Q2 2025.